The Life Sciences team advised Scholar Rock Holding Corporation on the completion of its $51.75 million follow-on public offering of common stock. The offering consisted of 3,450,000 shares at a price to the public of $15.00 per share, which included the full exercise of the underwriters’ option to purchase up to 450,000 additional shares of common stock. Scholar Rock received approximately $48.65 million in net proceeds from the transactions, after deducting underwriting discounts and commissions and other expenses related to the offering
Based in Cambridge, Massachusetts, Scholar Rock is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The Company’s novel understanding of the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level.
The Goodwin team was led by partners Kingsley Taft and Laurie Burlingame and associates Michael Rosenberg, Chloe Pletner, Carly Ward and Humza Bokhari and included partners Roger Cohen, Julie Tibbets, Daniel Karelitz and Ettore Santucci and associates Bryna Shmerling, Steve Tjoe and Alexander Plaum.
For additional details on the offering, please read the press release.